Tumors and the immune response interact in various ways. Tumors try to suppress the immune response in an effort to promote their growth and survival. The anti-tumor immune response, on the other hand, identifies tumor cells and kills them. Both tumors and the immune response elicit various mechanisms to combat the actions of the other.
The development of different classes of immunotherapies that target cancer cells continues to be a rapidly growing area of research. The development of diagnostic tests which can predict pat...
Date: November 19, 2020 Time: 8:00am PST, 11:00am EST Monoclonal antibody-based drugs have shown great potential as a treatment for several cancers. At Miltenyi Biotec, we offer a complete wo...
November 13, 2020 6:00 PM PST | November 14, 2020 10:00 AM SGT
Ensuring that clinical tests are not affected by tumor heterogeneity requires a sampling methodology that captures the genomic, proteomic, and cellular diversity of entire solid tumors. Howe...
November 13, 2020 4:00 PM PST | November 14, 2020 8:00 AM SGT
Three-dimensional (3D) cell culture spheroids and aggregates are preferred over monolayer cell culture due to their architectural and functional similarity to solid tumors. To study expressi...
Today's presentation will cover the following topics from the perspective of a NYC based Laboratory: What have we learned year to date about CoV-2 and specifically how diagnostic testing...
Ensuring that clinical tests are not affected by tumor heterogeneity requires a sampling methodology that captures the genomic, proteomic, and cellular diversity of entire solid tumors. Howe...
Three-dimensional (3D) cell culture spheroids and aggregates are preferred over monolayer cell culture due to their architectural and functional similarity to solid tumors. To study expressi...
Cancer cells can acquire immune resistance resulting in a loss of immunosurveillance. Tumor cells can upregulate PDL-1 which binds to PD-1. This complex inhibits CD8 Tumor Infiltrating cells...
DATE: Date needed, 2020 TIME: Time needed Exosomes are a population of naturally occurring mobile, membrane-limited, 30 – 100 nm in diameter, extracellular vesicles containing a large...
Comprehensive genomic profiling in clinical research studies helps to detect clinically relevant cancer driver mutations using low amount of tumor tissues within several days. Recent studies...
Comprehensive genomic profiling in clinical studies helps to detect clinically relevant cancer driver mutations using low amount of tumor tissues within several days. Recent studies have sho...
DATE: October 20th, 2020 TIME: 08:00am PT, 11:00am ET Tumor-associated macrophages (TAMs) are key cells in the tumor microenvironment (TME) with diverse immune functions that have a major in...
DATE: October 8, 2020 TIME: 1:00pm PDT Microsatellite instability (MSI) has evolved as a marker of potential hereditary cancer risk and is now a tissue agnostic immune biomarker with a broad...
Cancer disparities among persons of African descent are driven by both biological and nonbiological factors. There is evidence in breast cancer that psychosocial factors (environment, socioe...
Tumor phenotypes are dictated not only by the neoplastic cell component, but also by the tumor microenvironment (TME), which is inherently immuno-suppressive, is equipped to hamper effector...
Immune therapy approaches are being used in many different solid cancers today including clear cell renal carcinoma (mccRCC) and metastatic prostate adenocarcinoma. Over the past few years i...
Date: September 28, 2020 Time: 5:00pm (PDT), 8:00am (HKT), 9:00am (JST) Although there have been dramatic advances in the field of single-cell sequencing, current methods cannot be applied t...
New insights on the pathogenesis of COVID-19 7:00–7:30 pm PDT Presented By: Olaf Rötzschke, PhD The SIgN Mass Cytometry Platform (MCP) was originally established by Evan Newell, P...
Suspension by day, imaging by night: how to efficiently manage your system and optimize utilization Presented By: Jared K. Burks, PhD Mass cytometry, be it suspension or imaging, opens the d...
Speaker TBD 10:30–10:50 am PDT Exploring the immune tumor microenvironment of hepatocellular carcinoma with Imaging Mass Cytometry™ 10:50 am–11:10 am PDT Presented By: Won...
On measuring photons and ions: Impact on panel design, signal detection and data quality 10:30–11:00 am PDT Presented By: Tim Bushnell, PhD, MBA Monitoring immunotherapy with a mass cy...
The development of different classes of immunotherapies that target cancer cells continues to be a rapidly growing area of research. The development of diagnostic tests which can predict pat...
Date: November 19, 2020 Time: 8:00am PST, 11:00am EST Monoclonal antibody-based drugs have shown great potential as a treatment for several cancers. At Miltenyi Biotec, we offer a complete wo...
November 13, 2020 6:00 PM PST | November 14, 2020 10:00 AM SGT
Ensuring that clinical tests are not affected by tumor heterogeneity requires a sampling methodology that captures the genomic, proteomic, and cellular diversity of entire solid tumors. Howe...
November 13, 2020 4:00 PM PST | November 14, 2020 8:00 AM SGT
Three-dimensional (3D) cell culture spheroids and aggregates are preferred over monolayer cell culture due to their architectural and functional similarity to solid tumors. To study expressi...
Today's presentation will cover the following topics from the perspective of a NYC based Laboratory: What have we learned year to date about CoV-2 and specifically how diagnostic testing...
Ensuring that clinical tests are not affected by tumor heterogeneity requires a sampling methodology that captures the genomic, proteomic, and cellular diversity of entire solid tumors. Howe...
Three-dimensional (3D) cell culture spheroids and aggregates are preferred over monolayer cell culture due to their architectural and functional similarity to solid tumors. To study expressi...
Cancer cells can acquire immune resistance resulting in a loss of immunosurveillance. Tumor cells can upregulate PDL-1 which binds to PD-1. This complex inhibits CD8 Tumor Infiltrating cells...
DATE: Date needed, 2020 TIME: Time needed Exosomes are a population of naturally occurring mobile, membrane-limited, 30 – 100 nm in diameter, extracellular vesicles containing a large...
Comprehensive genomic profiling in clinical research studies helps to detect clinically relevant cancer driver mutations using low amount of tumor tissues within several days. Recent studies...
Comprehensive genomic profiling in clinical studies helps to detect clinically relevant cancer driver mutations using low amount of tumor tissues within several days. Recent studies have sho...
DATE: October 20th, 2020 TIME: 08:00am PT, 11:00am ET Tumor-associated macrophages (TAMs) are key cells in the tumor microenvironment (TME) with diverse immune functions that have a major in...
DATE: October 8, 2020 TIME: 1:00pm PDT Microsatellite instability (MSI) has evolved as a marker of potential hereditary cancer risk and is now a tissue agnostic immune biomarker with a broad...
Cancer disparities among persons of African descent are driven by both biological and nonbiological factors. There is evidence in breast cancer that psychosocial factors (environment, socioe...
Tumor phenotypes are dictated not only by the neoplastic cell component, but also by the tumor microenvironment (TME), which is inherently immuno-suppressive, is equipped to hamper effector...
Immune therapy approaches are being used in many different solid cancers today including clear cell renal carcinoma (mccRCC) and metastatic prostate adenocarcinoma. Over the past few years i...
Date: September 28, 2020 Time: 5:00pm (PDT), 8:00am (HKT), 9:00am (JST) Although there have been dramatic advances in the field of single-cell sequencing, current methods cannot be applied t...
New insights on the pathogenesis of COVID-19 7:00–7:30 pm PDT Presented By: Olaf Rötzschke, PhD The SIgN Mass Cytometry Platform (MCP) was originally established by Evan Newell, P...
Suspension by day, imaging by night: how to efficiently manage your system and optimize utilization Presented By: Jared K. Burks, PhD Mass cytometry, be it suspension or imaging, opens the d...
Speaker TBD 10:30–10:50 am PDT Exploring the immune tumor microenvironment of hepatocellular carcinoma with Imaging Mass Cytometry™ 10:50 am–11:10 am PDT Presented By: Won...
On measuring photons and ions: Impact on panel design, signal detection and data quality 10:30–11:00 am PDT Presented By: Tim Bushnell, PhD, MBA Monitoring immunotherapy with a mass cy...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
